What is Zacks Research's Forecast for ResMed Q1 Earnings?

ResMed Inc. (NYSE:RMD - Free Report) - Equities research analysts at Zacks Research lifted their Q1 2026 earnings per share estimates for shares of ResMed in a research report issued on Tuesday, November 12th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings per share of $2.25 for the quarter, up from their prior forecast of $2.13. The consensus estimate for ResMed's current full-year earnings is $9.28 per share. Zacks Research also issued estimates for ResMed's Q1 2027 earnings at $2.44 EPS.

A number of other research analysts have also recently commented on the stock. Royal Bank of Canada raised their price target on shares of ResMed from $224.00 to $232.00 and gave the stock a "sector perform" rating in a research note on Friday, October 25th. Bank of America boosted their price target on ResMed from $240.00 to $270.00 and gave the company a "buy" rating in a research note on Thursday, September 26th. Robert W. Baird increased their price objective on ResMed from $280.00 to $283.00 and gave the stock an "outperform" rating in a research note on Friday, October 25th. StockNews.com upgraded shares of ResMed from a "hold" rating to a "buy" rating in a research note on Tuesday, October 15th. Finally, Wolfe Research reaffirmed an "underperform" rating and set a $180.00 price target on shares of ResMed in a report on Wednesday, September 18th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $225.70.

ResMed Stock Performance

ResMed stock traded up $3.31 on Friday, hitting $234.74. The company's stock had a trading volume of 1,116,364 shares, compared to its average volume of 1,049,157. The firm has a market cap of $34.46 billion, a P/E ratio of 30.99, a price-to-earnings-growth ratio of 1.71 and a beta of 0.69. The company has a fifty day moving average price of $243.03 and a 200-day moving average price of $223.42. ResMed has a one year low of $147.39 and a one year high of $260.49. The company has a quick ratio of 1.91, a current ratio of 2.92 and a debt-to-equity ratio of 0.13.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.17. The firm had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.19 billion. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The company's quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the company posted $1.64 earnings per share.

Hedge Funds Weigh In On ResMed

Several hedge funds have recently made changes to their positions in the business. UMB Bank n.a. boosted its position in ResMed by 1.9% during the third quarter. UMB Bank n.a. now owns 2,465 shares of the medical equipment provider's stock valued at $602,000 after purchasing an additional 47 shares during the last quarter. Ascent Group LLC raised its position in shares of ResMed by 1.7% in the third quarter. Ascent Group LLC now owns 2,924 shares of the medical equipment provider's stock valued at $714,000 after purchasing an additional 48 shares during the period. Dorsey & Whitney Trust CO LLC lifted its position in ResMed by 3.7% during the first quarter. Dorsey & Whitney Trust CO LLC now owns 1,473 shares of the medical equipment provider's stock worth $292,000 after acquiring an additional 52 shares during the last quarter. QRG Capital Management Inc. boosted its stake in ResMed by 4.5% in the 2nd quarter. QRG Capital Management Inc. now owns 1,291 shares of the medical equipment provider's stock valued at $247,000 after purchasing an additional 56 shares during the period. Finally, Inspire Advisors LLC grew its stake in shares of ResMed by 1.9% in the second quarter. Inspire Advisors LLC now owns 3,060 shares of the medical equipment provider's stock valued at $586,000 after acquiring an additional 56 shares in the last quarter. 54.98% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider Kaushik Ghoshal sold 5,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $252.56, for a total transaction of $1,262,800.00. Following the completion of the sale, the insider now directly owns 21,788 shares of the company's stock, valued at approximately $5,502,777.28. This represents a 18.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael J. Farrell sold 14,683 shares of ResMed stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $248.38, for a total transaction of $3,646,963.54. Following the completion of the transaction, the chief executive officer now directly owns 464,169 shares in the company, valued at approximately $115,290,296.22. The trade was a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 63,056 shares of company stock valued at $15,086,020 in the last 90 days. 0.71% of the stock is owned by insiders.

ResMed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date is Thursday, November 7th. ResMed's dividend payout ratio (DPR) is currently 28.08%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.